{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to less than 50% death events.","groupId":"OG000","lowerLimit":"48","upperLimit":"NA","value":"335.5"},{"comment":"Upper limit of 95% CI was not estimable due to less than 50% death events.","groupId":"OG001","lowerLimit":"36","upperLimit":"NA","value":"251"},{"comment":"Upper limit of 95% CI was not estimable due to less than 50% death events.","groupId":"OG002","lowerLimit":"57","upperLimit":"NA","value":"180"},{"comment":"Upper limit of 95% CI was not estimable due to less than 50% death events.","groupId":"OG003","lowerLimit":"29","upperLimit":"NA","value":"76"},{"comment":"Median and limits of 95% CI were not estimable due to less than 50% death events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the first occurrence of objective response to first documented evidence of disease recurrence or progression. Participants without evidence of progression were censored at time of last evaluable disease assessment. Objective response was defined as any response of partial response/remission or better for all malignancies; for AML, a response of morphologic leukemia-free state is also included for ORR. Duration of response was calculated by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with DLBCL received Selinexor in different Schedules; Schedule 1: \\<= 12 milligram per square meter (mg/m\\^2) per orally (PO) alternating 3 times per week with twice weekly dosing (1 day between doses); Schedule 2: \\> 12 mg/m\\^2 PO 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly (1 day between doses) during Weeks 1 and 2; Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab intravenous (IV) once weekly for Weeks 1-4 during different cycles. Each cycle was of 28 days (Schedule 8: 21 days of cycle) or 10 scheduled selinexor doses.","id":"OG000","title":"Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with NHL received Selinexor in different Schedules; Schedule 1: \\<= 12 mg/m\\^2 PO alternating 3 times per week with twice weekly dosing (1 day between doses); Schedule 2: \\> 12 mg/m\\^2 PO 3 times weekly for week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs 1 day apart (Schedule 3); Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 days between doses) to evaluate vs twice weekly (Schedules 3, 4, 5, and 6); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly \\[1 Day between doses\\] during weeks 1 and 2; Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab IV once weekly for Weeks 1-4) during different cycles. Each cycle was of 28 days (Schedule 8: 21 days of cycle) or 10 scheduled selinexor doses.","id":"OG001","title":"Non-Hodgkin Lymphoma (NHL) Excluding DLBCL"},{"description":"Participants with MM received Selinexor in different Schedules; Schedule 1: \\<= 12 mg/m\\^2 PO alternating 3 times per week with twice weekly dosing (1 Day between doses); Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; 3 doses (36 mg/m\\^2 total) in the 1-week run-in period; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 6: \\>= 35 mg/m\\^2 PO twice weekly with dexamethasone (20 mg twice weekly) on Days of twice weekly Selinexor dosing; Schedule 11: Group A: 40 mg; Group B: 60 mg; Group C: 80 mg twice weekly (Weeks 1, 2, and 3) at 3 fixed dose levels during different cycles. Each cycle was of 28 days or 10 scheduled selinexor doses.","id":"OG002","title":"Multiple Myeloma (MM)"},{"description":"Participants with AML received Selinexor in different Schedules; Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3), Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 Days between doses) to evaluate vs. twice weekly (Schedules 3, 4, 5, and 6); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly (1 Day between doses) during Weeks 1 and 2; Schedule 10: \\>= 55 mg/m\\^2 PO twice weekly PO (Weeks 1 and 2) in participants with AML/18-Day treatment-free interval) during different cycles. Each cycle was of 28 days (for schedule 8: 21-day of cycle) or 10 scheduled selinexor doses.","id":"OG003","title":"Acute Myeloid Leukemia (AML)"},{"description":"Participants with other hematological malignancies (Acute lymphoblastic leukemia \\[ALL\\], Chronic myelogenous leukemia \\[CML\\] and chronic lymphocytic leukemia \\[CLL\\]) received Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly \\[1 day between doses\\]; Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 Days between doses) to evaluate vs. twice weekly (Schedules 3, 4, 5, and 6); Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab IV once weekly for Weeks 1-4 during different cycles. Each cycle was of 28 days or 10 scheduled selinexor doses.","id":"OG004","title":"Other Hematological Malignancies (ALL, CML and CLL)"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis included all participants who had either completed 1 cycle of treatment or discontinued treatment prior to completing the first cycle due to documented disease progression, death related to disease, or treatment-related toxicity. Here 'Overall Number of Participants Analyzed' signifies number of participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug administration to end of treatment (up to 27 months)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Days"}